The antiviral drug having dual antiviral activity against HIV and HBV is:

Correct Answer: A. Emtricitabine

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with the unique property of dual antiviral activity against both HIV and HBV. This is the discriminating fact that sets it apart from other antiretrovirals. The mechanism is identical for both viruses: emtricitabine is phosphorylated intracellularly to its active triphosphate form, which then inhibits reverse transcriptase by chain termination. In HIV therapy, it is a backbone component of first-line regimens in India (per NACO guidelines), typically combined with tenofovir and an INSTI or NNRTI. Critically, emtricitabine also inhibits HBV reverse transcriptase with high potency, making it the preferred NRTI choice when treating HIV-HBV coinfection—a scenario not uncommon in India given the epidemiology of both infections. When used as monotherapy for HBV, resistance emerges rapidly; hence it is always combined with other agents. The dual activity is a direct consequence of structural similarity between HIV and HBV reverse transcriptases in their nucleoside binding pockets. This property is tested frequently in NEET PG because it is clinically relevant for managing coinfected patients and represents a key pharmacological distinction among NRTIs.

Why the other options are wrong

B. Ritonavir — Ritonavir is a protease inhibitor (PI) that acts on HIV protease only; it has no activity against HBV. Although ritonavir is used as a pharmacokinetic booster in modern HIV regimens (at low doses), it does not inhibit HBV reverse transcriptase or any HBV enzyme. This is a common trap—students may confuse 'potent antiretroviral' with 'dual activity.' Ritonavir's only role is to inhibit CYP3A4, prolonging levels of other PIs. C. Enfuvirtide — Enfuvirtide is a fusion inhibitor (entry inhibitor) that blocks HIV envelope protein interaction with CD4 receptors; it has zero activity against HBV. It is a parenteral agent reserved for treatment-experienced, multi-drug-resistant HIV patients in India and does not target any HBV replication step. The NBE trap here is pairing 'newer' or 'potent' antiretrovirals with broad activity—enfuvirtide is neither broad nor oral. D. Abacavir — Abacavir is an NRTI like emtricitabine and inhibits HIV reverse transcriptase effectively, but it has NO activity against HBV. Although both are nucleoside analogues, abacavir's structure does not permit efficient phosphorylation or binding in the HBV reverse transcriptase active site. The trap is that students may assume all NRTIs are interchangeable; in fact, only emtricitabine and lamivudine (another NRTI) have dual HIV-HBV activity.

High-Yield Facts

Mnemonics

DUAL NRTIs (HIV + HBV) FTC & 3TC = Emtricitabine & Lamivudine. These two NRTIs alone have dual activity. Remember: FTC and 3TC are the only two. Antiretroviral Classes & HBV Activity PIs, INSTIs, NNRTIs, EIs = HIV only. NRTIs (FTC, 3TC) = HIV + HBV. Use this when ruling out other drug classes.

NBE Trap

NBE pairs emtricitabine with other 'potent' antiretrovirals (ritonavir, enfuvirtide) to test whether students know that potency against HIV does not equal dual activity. The key discriminator is reverse transcriptase inhibition in both viruses, not general antiretroviral strength.

Clinical Pearl

In Indian clinical practice, when an HIV-positive patient is found to be HBsAg-positive (coinfection), emtricitabine or lamivudine must be included in the ART regimen to prevent HBV flares and resistance. Abrupt discontinuation of these agents in coinfected patients can trigger severe hepatitis—a critical bedside pearl for managing Indian patients with dual infection.

_Reference: KD Tripathi Pharmacology Ch. 88 (Antiretrovirals); NACO National Guidelines on ART (2017 revision)_